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1. Introduction 
 
A histologically positive SLN is an important prognostic factor for survival and 
the risk of recurrence [4; 8; 9], the absence of metastases in the SLN implies 
that the entire lymph node basin is tumour-free [7]. 
Since 1996, Sentinel lymph node dissection (SLND) has been performed at the 
Department of Dermatology, University of Tuebingen in Germany, to stage and 
identify patients with cutaneous melanoma who may benefit from an early, 
complete lymphadenectomy (CLA) and adjuvant therapy. Originally initiated by 
Morton et al. [15], the SLND technique offered the possibility to identify patients 
who harbour lymph node micrometastases by using this minimally invasive 
procedure, while potentially sparing lower risk patients from undergoing CLA [1]. 
Because in the majority of cases the first spreading of the tumour takes place to 
the regional lymph nodes, SLND emerged in the last few years [15; 20]. Today 
SLND is the nodal staging procedure of choice in patients with clinically non-
metastatic cutaneous melanoma [5].  
The aim of the present study was to explore the histopathological and clinical 
risk factors for a positive SLND and to examine the role of individual surgeons 
and their SLND experience on SLN results.  
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2. Patients and Methods 
2.1 Patients 
This study includes 999 consecutive patients (547 male / 452 female) with 
clinical stage I/II cutaneous melanoma who were prospectively followed up from 
January 2000 to October 2006 at the Department of Dermatology at the 
University of Tuebingen. The SLND was generally offered to patients having a 
melanoma with a thickness ≥ 1.00mm or having a melanoma thinner than 
1.00mm with histological regression or ulceration.  
In 21 patients with a melanoma < 1.00mm and without regression or ulceration 
there was a strong demand by the patient and/or the referring physicians to 
perform SLND. The routine preoperative clinical and technical examinations 
(ultrasound of the regional lymph nodes, chest x-ray, abdominal ultrasound or 
computed tomography) didn‟t disclose any evidence for regional or distant 
metastases. The patients had given written informed consent to documentation 
and evaluation of their data stored in the Central Malignant Melanoma Registry 
of the German Dermatological Society and the Melanoma Registry of the 
Department of Dermatology at the University of Tuebingen. 
 
2.2 Sentinel Lymph Node Dissection (SLND) 
SLND was performed using the so-called triple-technique (lymphoscintigraphy, 
gamma-probe & blue dye injection), thus the SLN could be distinguished from 
other lymph nodes of the draining lymphatic basin. The method of SLN 
identification has been described previously [15]. SLND was performed using 
tumescent local anaesthesia prior to the injection of patent blue V [3]. 
Lymphoscintigraphy: 
Preoperatively lymphoscintigraphy was performed to detect the draining lymph 
node basin. Five to 20 hours before the operation, 30-100 MBq Technetium 
nanocolloids were carefully injected into the dermis in equal amounts in 4 to 6 
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parts around the localization of the primary tumour, respectively close to the 
melanoma excisions scar. After several minutes lymphoscintigraphy was 
conducted, until the first appearance of SLN. 
Detection via gamma-probe: 
The SLN was localized by a transdermal measurement of radioactivity with a 
hand-held gamma-probe (C-Trak Automatic. Morgan Hill,Ca). 
Preoperative blue dye injection: 
Ten minutes before skin incision, 0.5 to 1 ml of isosulfane blue (Patent blue V, 
Byk Gulden) was injected intradermally around the tumour respectively the 
previous excision site.  
Following a skin incision, the sentinel node or several sentinel nodes were 
isolated and dissected. Intraoperative identification of the sentinel nodes were 
facilitated by the greatest radioactivity, which was shown by the gamma probe, 
and the blue dye of the marked sentinel lymph nodes. All blue nodes and/or 
nodes whose radioactivity in vivo clearly exceeded the background radioactivity 
of the lymph node region were removed. Ex vivo the radioactivity was confirmed 
within the SLN by gamma probe. 
 
2.3 Histopathological Evaluation 
In 802 of 976 patients, SLNs were bisected, one half being used for routine 
pathology and the other half for study purposes. SLNs from the remaining 174 
patients were entirely sent to histopathological evaluation. 
The excised lymph nodes were fixed in 5% formaldehyde, embedded in paraffin 
and analyzed by standard histopathology (haematoxilin and eosin staining) and 
immunohistochemistry. SLNs were cut into 5 sections. Two slices were used for 
standard H&E staining and three for immunohistochemical studies with Anti-
HMB45, Anti-S100 and Anti-MELAN A. In standard H&E staining a distance of 
approximately 200-400 µm between the sections was followed. 
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A SLND was defined as positive when tumour cells could either be identified in 
the H&E-stained specimens or when HMB45 positive solitary cells as well as 
cell aggregates of S100 positive cells emerged in immunohistochemical 
investigations.  
 
2.4 Surgeons 
In this study we investigated the SLN results of 22 different surgeons in our 
Department, including the 4 principal surgeons, who had each performed more 
than 100 SLN procedures. Of the four principal surgeons, surgeon A had 
performed 124 procedures, surgeon B 321 procedures, surgeon C 171 
procedures and surgeon D 162 procedures. The remaining surgeons had each 
performed between one and 100 SLN procedures. We classified the surgeons 
in 3 groups. Group 1 had an experience of less than 25 SLN procedures (16 
surgeons, accounting for 63 procedures), group 2 from 25 to 100 (2 surgeons, 
accounting for 106 procedures) and group 3 with more than 100 SLN 
procedures (4 surgeons, accounting for 778 procedures).  
If more than one surgeon was involved in a SLND, we evaluated the most 
experienced surgeon. 
 
2.5 Statistical Methods 
For the statistical evaluation the program JMP 7.0 was used 
(http://www.jmp.com/). Univariable analysis of dichotomous variables (e.g. sex) 
were analyzed with the Pearson‟s chi-square test [12].Variables having more 
than two values (e.g. histological subtype) were studied using the likelihood 
ratio test.  
In the multivariable analysis a logistic regression analysis (nominal logistic 
regression) was carried out with a stepwise backward elimination of non-
significant variables to detect independent prognostic factors and their 
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interactions. Statistical significance was tested using the likelihood ratio test. A 
p-value less than 0.05 was considered as statistically significant.  
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3. Results 
3.1 Clinical and histological risk factors 
Between January 2000 and October 2006, SLND was intended in 999 patients 
with clinical stage I and II cutaneous melanoma. There were 5 patients, in which 
a lymph node was radioactively labelled but surgery was not performed due to 
SLN‟s localization in the deep abdomen or behind the carotid artery. In 7 
patients histological examination revealed that the tissue removed was only 
adipose or connective tissue. In 11 cases a SLN was not detectable intra-
operatively or surgery was stopped due to the localization of the marked SLN 
e.g. adjacent to the facial nerve (Figure 1).  
Among the remaining 976 patients SLND was positive in 14.34% (140 patients) 
and negative in 85.66% (836 patients). The patients‟ age ranged from 10 years 
to 89 years (median, 59 years).  
Clinical and histological risk factors for metastasized cutaneous melanoma are 
summarized in table 1. 
Sex, age and localization 
Men were shown to have a higher risk for a metastasizing melanoma than 
women. Age was not a significant factor for a positive SLND. Concerning the 
localization of the primary tumour there was a lower risk for melanoma of the 
upper extremity (n=12 of 154, 7.79%) than for those located on the head and 
neck (n=16 of 111, 14.41%), trunk (n=56 of 372, 15.05%) and lower extremity 
(n=56 of 339, 16.52%).  
Tumour thickness 
Tumour thickness was highly significant in predicting a positive SLN (p<0.0001). 
Tumour thickness ranged from 0.35mm to 20.00mm. The median tumour 
thickness was 1.80mm. The distribution of the tumour thickness among the 
patients is summarized in table 1. 
9 
 
Histological tumour type and further histological features 
A highly significant factor for positive SLNs was the histological tumour type 
(p≤0.0001). The smallest proportion of positive SLNs was observed in LMM 
(lentigo maligna melanoma) (2.78%; n=1 of 36, tumour thickness 2.75mm, 
located on the face). The median tumour thickness of LMM was 1.55mm (range 
from 0.75mm to 4.90mm, mean 1.76mm). In the univariable analysis of LMM 
versus the other histological types (ALM, NM, SSM) there was a significant 
benefit in the SLN results (p=0.044) for those patients with a LMM. In the 
multivariable analysis there was no advantage considering the SLN status in 
those patients (p=0.067). Patients with an ALM (acral lentiginous melanoma) 
had a SLN positivity rate of 22.73% (n=20 of 88). The median tumour thickness 
in all patients with an ALM was 3.00mm.  
Histological ulceration of the primary tumour was a significant risk factor for a 
positive SLND (p≤0.0001), histological regression and nevus association were 
not. 
Interestingly there was no significant statistic difference whether complete 
(n=174) or bisected (n= 802) SLNs were evaluated. 
 
3.2 Influence of the different surgeons 
One aim of this study was to assess if the outcome of sentinel node biopsy 
depended on a surgeon‟s qualification. In 947 SLND we were able to evaluate 
the surgeon‟s experience in the SLND procedure (Table 2). Interestingly there 
was no significant correlation between the practical experience of the surgeons 
and SLND results (p=0.752). Surgeons who had performed less than 25 SLNDs 
detected a positive SLN in 14.29% (n=9 of 63), those who had performed SLND 
between 25 and 100 times had a positivity rate of 11.32% (n=12 of 106) and 
surgeons with the most experience (>100 SLN procedures) revealed a positive 
SLN in 13.88% (n=108 of 778). 
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Among the surgeons there were 4 principal surgeons, who had performed the 
SLND between 124 and 321 times in the study period. The rate of positive 
SLND ranged from 9.68% (n=12 of 124) to 16.96% (n=29 of 171) for each 
surgeon (p=0.30). Furthermore no statistical difference was demonstrated 
between the SLND results of the 4 principal surgeons and the surgeons who 
had operated less than 100 times (p=0.40). 
Multivariable logistic regression analysis 
Logistic regression analysis with stepwise backward elimination of non-
significant variables was performed to identify factors correlating significantly 
with positive SLNs including the following factors in the model: sex, tumour 
thickness, histological tumour type, ulceration, and tumour localization. Because 
we noticed a better prognosis for primary melanomas of the upper extremies, 
we compared this site with head and neck, trunk and lower extremities       
(Table 3). 
Increasing tumour thickness, ulceration and a tumour site on head and neck, 
trunk or lower extremities were independent significant factors for metastasis to 
the SLN.  
We also evaluated the surgeons‟ impact in various models showing no effect of 
the surgeons‟ role on the SLND. 
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4. Discussion 
4.1 Clinical and histological risk factors 
The SLND positivity rate of 14.34% in this series is relatively low compared to 
the literature (11.9%-29%) [4; 5; 9; 10; 11; 16]. This might be explained by the 
high proportion of thin and intermediate lesions (≤2.00mm) in this cohort 
(57.56%) and, in part, by the number of histopathological slices analyzed per 
lymph node (no serial sections were done). It is known that the rate of SLN 
positivity does increase with the histopathological work-up of the biopsies. 
In the multivariable analysis increasing tumour thickness, ulceration and defined 
localizations such as head and neck, trunk and lower extremity were identified 
as risk factors for metastasis to a SLN. 
With increasing tumour thickness the proportion of histopathologically positive 
SLNs rises [4; 8; 9; 10; 15; 20; 24]. In our series tumour thickness was the most 
important risk factor for a positive SLND. Metastasis to the SLN was identified in 
only 1.15% of the patients having a tumour thickness ≤ 1.00mm, in 8.6% of 
those with a tumour thickness of 1.01 to 2.00mm, in 18.06% of the cases with 
tumour thickness of 2.01 to 4.00mm and in 36.80% of the patients with tumour 
thickness >4.00mm.  
Histological ulceration of the primary tumour was strongly associated with a 
positive SLND. This finding is corroborated by other investigations when 
equivalent methods had been used [8; 9; 14]. 
Localization of the melanoma on the head and neck area, the trunk or the lower 
extremities was observed with a two-fold odds ratio for a positive SLND. The 
effect of localization was independent from tumour thickness, ulceration or the 
histological type. 
Remarkably only 1 of 36 LMM patients (2.78%) had a positive SLND (2.75mm; 
LMM in the face). In the univariable analysis patients with LMM had significantly 
more negative SLNBs than other tumour types. In the multivariable analysis 
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only tumour thickness, histological ulceration and localization remained 
significant. Here, the question rises, wether it is reasonable to perform SLND on 
patients having a LMM which predominantly is located in the head and neck 
area. The low probability of a positive SLN in LMM and a moderate benefit of 
the SLND procedure have to be balanced against the surgical risk of scar 
formation and facial nerve damage. 
Interestingly the presence of histological regression was more frequently 
associated with a negative SLN (9.32% vs. 15.03%, p=0.097) in our study. This 
observation seems to be controversial with respect to the general clinical 
assumption that before the onset of regression the tumour had been even 
thicker. But it was reported before by Paek et al. [16]. A potential explanation 
could be a potent immune response of the host against the aggressive tumour 
thus reducing metastases or other mechanism like oncogene and growth 
factors [17]. 
In our analysis we didn‟t incorporate the risk factors mitotic index, lymphocytic 
infiltration and satellitosis. However, in the literature increasing mitotic rate 
(especially in younger patients) and angiolymphatic invasion were mentioned as 
risk factors which were associated with a greater likelihood of positive SLN 
status [16]. Especially in ALM the presence of microsatellites and a high mitosis 
rate were independently correlated with survival [18]. 
We did not use micromorphometric features. The “s-classification” by Starz et 
al. [22] includes the number of millimetric slices involved by metastasis and 
depends on the maximum depth of invasion of melanoma cells towards the 
centre of the lymph node. Thereupon,  subgroups of patients were defined who 
might have a greater benefit from SLND than others [6; 21; 22]. 
 
4.2 Influence of the different surgeons 
One essential aim of this study was to clarify the surgeon‟s impact on the result 
of the SLND. Here, the SLND results of all surgeons were evaluated in a 
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retrospective manner for 947 patients from January 2000 to October 2006. At 
the Department of Dermatology of the University of Tuebingen SLND has been 
the standard procedure since 1996. In former publications a direct correlation 
between the success in identifying the SLNs and the number of procedures 
performed by each surgeon was documented [14; 15; 20]. A “learning curve” 
was denoted and the triple-technique was recommended to be performed only 
by physicians with suitable training [2; 5; 14; 15; 19; 20; 23]. Morton and 
colleagues indicated that a learning phase of 30 cases may not be sufficient for 
lymphatic mapping and SLND, and suggested a minimum of 55 cases to 
identify the SLN with 95% accuracy [13]. 
In contrast, our results did not show a significant correlation between the 
numbers of procedures per surgeon and the SLN positivity (p=0.752). Perhaps 
these good results of “beginners” may be influenced by training and supervision 
of less experienced surgeons by an experienced consultant, who guided 
through the SLN procedures. Ultimately there seems to be no learning curve 
when “beginners” are supervised. 
 
4.3 Conclusions 
The surgeons‟ experience did not play a significant role on the result of a SLND. 
Fortunately the “beginners” were supervised and not “left alone”.  There seems 
to be no learning curve when “beginners” are supervised.  
Multivariable analysis demonstrated increasing tumour thickness, ulceration as 
well as defined localizations of the primary tumour like head and neck, trunk 
and lower extremity to be independent risk factors for a positive SLND. Based 
on this study and the literature, a model for calculating the risk of a histological 
positive SLN could be derived. Such a model might improve the present 
inclusion criteria for SLND beyond tumour thickness. 
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5. Summary 
 
Background:  Patients with early stage I and II cutaneous malignant melanoma 
have a good prognosis after surgical excision of the primary tumour. The 
sentinel lymph node (SLN) status is known to be one of the most important 
predictive factors. The accuracy of the SLN‟s detection is attributed to the 
surgeons‟ practical experience. 
Objectives: The aim of this study was to define risk factors for SLN metastasis 
in malignant melanomas and to investigate the impact of individual surgeons on 
the results of SLN dissection (SLND). 
Patients and methods: 999 consecutive patients with stage I/II melanoma 
underwent lymphatic mapping for SLND in the Department of Dermatology, 
University of Tuebingen, from January 2000 to October 2006. 978 patients had 
a tumour thickness ≥1.00mm or <1.00mm and regression or ulceration. 21 
patients were included having a tumour thickness <1.00mm without ulceration 
or regression. Clinical, histological and surgical parameters were studied with 
reference to SLN metastasis using univariable and multivariable analysis. 
Moreover we evaluated the SLND results in relation to the surgeons and their 
professional experience in SLND. 
Results: 14.34% of the sentinel lymph nodes contained tumour -cells. Using 
multivariable logistic regression analysis with successive elimination of non-
significant variables, significant parameters for SLN metastasis were sex 
(p=0.05), tumour thickness (p≤0.0001), ulceration (p=0.02) and defined 
localizations (p=0.03) like head and neck, trunk and lower extremity. SLN 
results were not different in surgeons who performed less than 100 SLND 
compared to surgeons with an experience ≥100 SLNB. Positivity of SLNs in 
relation to the 4 main surgeons ranged from 9.68% to 16.96%, but was neither 
statistically significant in univariable nor in multivariable analysis. 
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Conclusions: Increasing tumour thickness, histological tumour type (acral 
lentiginous melanoma, nodular melanoma), ulceration, tumour localization on 
head and neck, trunk and lower extremity and male sex were associated with a 
greater probability of positive SLN status. There was no statistically significant 
correlation between surgeons and SLN results. The results of the present study 
support the use of other parameters beyond tumour thickness to select for 
SLND in patients with malignant melanoma. 
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6. Summary in German 
 
Der Status des Wächterlymphknotens wird als einer der prognostisch 
wichtigsten Faktoren im klinischen Stadium I und II des malignen Melanoms der 
Haut gesehen. Die Genauigkeit des Auffindens des Wächterlymphknotens wird 
dabei der praktischen Erfahrung des Operateurs zugeschrieben. 
Ziel dieser Studie war darzustellen, welche Risikofaktoren zur Metastasierung in 
die Wächterlymphknoten beim malignen Melanom der Haut beitragen. Als 
weiterer Schwerpunkt  wurde untersucht, welche Auswirkungen die einzelnen 
Operateure auf das Ergebnis der Wächterlymphknotenbiopsie haben. 
Bei 999 aufeinander folgenden Patienten der Universitäts-Hautklinik Tübingen 
mit einem malignen Melanom der Haut Stadium I und II  wurde eine Darstellung 
der Lymphgefäße vorgenommen. Klinische, histologische und chirurgische 
Parameter wurden bezüglich einer Metastasierung in die Wächterlymphknoten 
untersucht. Dafür wurden univariate und multivariate Analysen durchgeführt. 
Tumorzellen waren in 14.34% aller Wächterlymphknoten enthalten. 
Zunehmende Tumordicke, der histologische Tumortyp (akrolentiginöses 
Melanom, noduläres Melanom), Ulzeration, Tumorlokalisation an Kopf, Hals, 
Stamm und unterer Extremität sowie männliches Geschlecht waren in der 
univariaten Analyse verbunden mit einer größeren Wahrscheinlichkeit eines 
positiven Wächterlymphknotens. In der multivariaten Auswertung waren 
Tumordicke, Ulzeration und die Lokalisation (andere versus obere Extremität) 
unabhängige Risikofaktoren für eine Metastasierung in den 
Wächterlymphknoten. Die Ergebnisse der Wächterlymphknotenbiopsie 
unterschieden sich nicht hinsichtlich der Erfahrung der Operateure. So 
erreichten diejenigen, welche bisher weniger als 100 Biopsien durchgeführt 
hatten,  ähnliche Ergebnisse wie erfahrenere Chirurgen mit 100 oder mehr 
Wächterlymphknotenbiopsien. 
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Schlussendlich konnten wir keinen signifikanten Zusammenhang zwischen den 
einzelnen Operateuren und den Ergebnissen der Wächterlymphknotenbiopsie 
feststellen. Neben Tumordicke spielen noch andere Faktoren wie die Ulzeration 
und Lokalisation im Hinblick auf die Auswahl der Patienten für eine 
Wächterlymphknotenbiopsie eine Rolle.  
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7. Figures and Tables        
           
Figure 1: 999 patients subdivided into 5 groups (flow chart) 
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Table 1: Clinical and histological risk factors for metastasized malignant 
melanoma. Univariable analysis 
 
Variable SLND 
pos. 
 SLND 
neg. 
 SLND 
total 
 
 n % n % n p-value 
 140 14.34 836 85.66 976  
       
Patients„ sex       
Male 89 16.57 448 83.43 537  
Female 51 11.62 388 88.38 439 0.028 
       
Age       
Min. (years) 15  10  10  
Max. (years) 89  87  89  
Median (years) 54.5  59  59.00 0.152 
       
Localization       
Head/Neck 16 14.41 95 85.59 111  
Trunk 56 15.05 316 84.95 372  
Upper extremities 12 7.79 142 92.21 154  
Lower extremities 56 16.52 283 83.48 339 0.053 
       
Tumour thickness  
(mm) 
      
Min. 0.90  0.35  0.35  
Max. 15.00  20.00  20.00  
Median 2.95  1.70  1.80 <0.0001 
       
Tumour thickness 
(mm) 
      
< 0.75mm 0 0.00 14 100.0 14  
0.75 - 1,00mm 1 1.37 72 98.63 73  
1,01 - 2,00mm 41 8.61 435 91.39 476  
2,01 - 4,00mm 52 18.06 236 81.94 288  
> 4,00 mm 46 36.80 79 63.20 125 < 0.0001 
       
Histological Tumour 
Type 
      
LMM 1 2.78 35 97.22 36  
other 139 14.79 801 85.21 940 0.044 
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Table 1 (continued.): Clinical and histological risk factors for metastasized 
cutaneous melanoma. Univariable analysis 
 
Variable SLND 
pos. 
 SLND  
neg. 
 SLND 
total 
 
 n % n % n p-value 
 140 14.34 836 85.66 976  
       
Histological Tumour 
Type 
      
SSM 55 10.60 464 89.40 519  
NM 48 21.24 178 78.76 226  
LMM 1 2.78 35 97.22 36  
ALM 20 22.73 68 77.27 88  
other 16 14.95 91 85.05 107 <0.0001 
       
Histological Ulceration       
Ulceration 66 24.44 204 75.56 270  
No Ulceration 74 10.48 632 89.52 706 <0.0001 
       
Histological  
Regression 
      
Regression 11 9.32          107 90.68 118  
No Regression 129 15.03 729 84.97 858 0.097 
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Table 2: Surgical experiences in SLND 
 SLND 
pos. 
 SLND 
neg. 
 SLND 
Total 
 
 n % n % n p-value 
 140 14.34 836 85.66 976  
Missing values 11  18  29  
Data on surgeons 
available 
129 13.62 818 86.38 947  
       
Surgeon‟s experience       
<25 SLND 9 14.29 54 85.71 63  
25-100 SLND 12 11.32 94 88.68 106  
>100 SLND 108 13.88 670 86.12 778 0.752 
       
Surgeons >100 SLND 108 13.88 670 86.12 778  
Surgeons ≤100 SLND 21 12.43 148 87.57 169 0.617 
       
Principal Surgeons       
Surgeon 1 12 9.68 112 90.32 124  
Surgeon 2 42 13.08 279 86.92 321  
Surgeon 3 29 16.96 142 83.04 171  
Surgeon 4 25 15.43 137 84.57 162  
all other Surgeons 21 12.43 148 87.57 169 0.400 
 
 
Table 3: Multivariable analysis of risk factors for a positive sentinel node  
Risk factor Odds ratio Lower CI Upper CI p-value 
(log) Tumour 
thickness (in 
mm) per unit of 
magnitude 
18.45 8.82 39.40 <0.0001 
Histological 
ulceration yes 
vs. no 
1.55 1.03 2.32 0.038 
Other regions 
vs. upper 
extremity  
2.10 1.15 4.15 0.014 
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